Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

HC Wainwright & Co. Maintains Buy on MannKind, Lowers Price Target to $6

HC Wainwright & Co. analyst Oren Livnat maintains MannKind (NASDAQ:MNKD) with a Buy and lowers the price target from $6.5 to $6.

byBenzinga Newsdesk

February 28, 2022

1 minute read

HC Wainwright & Co. analyst Oren Livnat maintains MannKind (NASDAQ:MNKD) with a Buy and lowers the price target from $6.5 to $6.

Chardan Capital Maintains Buy on Provention Bio, Raises Price Target to $24

By Benzinga Newsdesk

Today, 2:05 AM

Chardan Capital analyst Geulah Livshits maintains Provention Bio (NASDAQ:PRVB) with a Buy and raises the price target from $21 to $24.

PRVB

Recap: Pinnacle West Capital Q2 Earnings

By Benzinga Insights

Today, 2:05 AM

Pinnacle West Capital (NYSE:PNW) reported its Q2 earnings results on Wednesday, August 3, 2022. Here's what investors need to know about the announcement.

PNW

Global
News

White House Expected To Announce Around $1B Of Artillery, Anti-ship Missiles And Other Weaponry For Ukraine

By Benzinga Newsdesk

Today, 2:05 AM

- Reuters

RSX

Inflation Continues To Cool, But At Slower Pace Than Economists Predicted: Stocks Struggle To Price In The Fed’s Next Move

By Adam Eckert

Today, 2:05 AM

The SPDR S&P 500 (NYSE: SPY) is volatile Tuesday morning after the Labor Department reported a 6.4% year-over-year increase in the consumer price index for January, marking the fourth straight lower print.

SPY

HC Wainwright & Co. Maintains Buy on MannKind, Lowers Price Target to $6

Related Posts

Chardan Capital Maintains Buy on Provention Bio, Raises Price Target to $24

Recap: Pinnacle West Capital Q2 Earnings

White House Expected To Announce Around $1B Of Artillery, Anti-ship Missiles And Other Weaponry For Ukraine

Inflation Continues To Cool, But At Slower Pace Than Economists Predicted: Stocks Struggle To Price In The Fed’s Next Move